Current state of adjuvant therapy in resected pancreatic adenocarcinoma
2006 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 45, no 2, 124-135 p.Article, review/survey (Refereed) Published
Pancreatic carcinoma cannot generally be cured by surgery alone. This review summarizes the development of adjuvant therapy over the past two decades. Four randomized controlled trials compare long-term survival of different treatments. The small GITSG-study supports combined chemoradiation, but the EORTC-study found no significant effect. A Norwegian study of adjuvant chemotherapy found an increased median survival, but no effect beyond two years. The large ESPAC-1 study shows a benefit for 5-FU based chemotherapy, while chemoradiation had a negative effect. Thus, evidence favours adjuvant therapy, but 5-FU may not be the ultimate drug. Support for gemcitabine is given by preliminary data from a German randomized trial, and further American and European studies are upcoming. However, postoperative therapy is problematic, as 20-30% of resected patients never undergo treatment because of slow recovery or other reasons. Preoperative therapy has some theoretical advantages, and moreover, patients with rapidly progressive disease may be spared surgery. Randomized controlled trials are lacking, but published results compare well with postoperative, adjuvant therapy. The value of locally targeted therapy is difficult to assess. Reasonable results have been obtained with regional chemotherapy, whereas intraoperative radiotherapy does not seem to increase survival despite reducing reducing local recurrences.
Place, publisher, year, edition, pages
Informa Healthcare, 2006. Vol. 45, no 2, 124-135 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-101361DOI: 10.1080/02841860600554238PubMedID: 16546857OAI: oai:DiVA.org:liu-101361DiVA: diva2:666093